CN110530829A - 一种基于荧光的早期药物筛选方法 - Google Patents
一种基于荧光的早期药物筛选方法 Download PDFInfo
- Publication number
- CN110530829A CN110530829A CN201910770631.4A CN201910770631A CN110530829A CN 110530829 A CN110530829 A CN 110530829A CN 201910770631 A CN201910770631 A CN 201910770631A CN 110530829 A CN110530829 A CN 110530829A
- Authority
- CN
- China
- Prior art keywords
- fluorescence
- drug
- gaba
- target spot
- ion channel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 58
- 238000007877 drug screening Methods 0.000 title claims abstract description 22
- 102000004310 Ion Channels Human genes 0.000 claims abstract description 32
- 239000003814 drug Substances 0.000 claims abstract description 31
- 229940079593 drug Drugs 0.000 claims abstract description 28
- 230000008484 agonism Effects 0.000 claims abstract description 9
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 9
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims description 50
- 210000004027 cell Anatomy 0.000 claims description 49
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims description 46
- 238000001514 detection method Methods 0.000 claims description 30
- 102000027484 GABAA receptors Human genes 0.000 claims description 15
- 108091008681 GABAA receptors Proteins 0.000 claims description 15
- 210000000170 cell membrane Anatomy 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 6
- 102000005915 GABA Receptors Human genes 0.000 claims description 4
- 108010005551 GABA Receptors Proteins 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 230000035945 sensitivity Effects 0.000 claims description 4
- 241001614291 Anoplistes Species 0.000 claims 1
- 230000004907 flux Effects 0.000 abstract description 9
- 238000012216 screening Methods 0.000 description 30
- 108090000862 Ion Channels Proteins 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 21
- 239000000975 dye Substances 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 210000003169 central nervous system Anatomy 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 5
- 108091006146 Channels Proteins 0.000 description 5
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 5
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 206010067484 Adverse reaction Diseases 0.000 description 4
- 230000006838 adverse reaction Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LHNKBXRFNPMIBR-UHFFFAOYSA-N Picrotoxin Natural products CC(C)(O)C1(O)C2OC(=O)C1C3(O)C4OC4C5C(=O)OC2C35C LHNKBXRFNPMIBR-UHFFFAOYSA-N 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- 229960000794 baclofen Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000007831 electrophysiology Effects 0.000 description 2
- 238000002001 electrophysiology Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000012188 high-throughput screening assay Methods 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 238000012402 patch clamp technique Methods 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- VJKUPQSHOVKBCO-AHMKVGDJSA-N picrotoxin Chemical compound O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(=C)C)[C@@H]1C(=O)O2.O=C([C@@]12O[C@@H]1C[C@]1(O)[C@@]32C)O[C@@H]3[C@H]2[C@@H](C(C)(O)C)[C@@H]1C(=O)O2 VJKUPQSHOVKBCO-AHMKVGDJSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- MEXAGTSTSPYCEP-JEDNCBNOSA-N (2s)-2,6-diaminohexanoic acid;hydrobromide Chemical compound Br.NCCCC[C@H](N)C(O)=O MEXAGTSTSPYCEP-JEDNCBNOSA-N 0.000 description 1
- 239000003140 4 aminobutyric acid A receptor blocking agent Substances 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229940090502 GABA A receptor antagonist Drugs 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- -1 HygromycinB Chemical compound 0.000 description 1
- 102000004086 Ligand-Gated Ion Channels Human genes 0.000 description 1
- 108090000543 Ligand-Gated Ion Channels Proteins 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- PPTYJKAXVCCBDU-UHFFFAOYSA-N Rohypnol Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1F PPTYJKAXVCCBDU-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 229910002090 carbon oxide Inorganic materials 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 229960001690 etomidate Drugs 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002102 hyperpolarization Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
Landscapes
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910770631.4A CN110530829A (zh) | 2019-08-20 | 2019-08-20 | 一种基于荧光的早期药物筛选方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910770631.4A CN110530829A (zh) | 2019-08-20 | 2019-08-20 | 一种基于荧光的早期药物筛选方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110530829A true CN110530829A (zh) | 2019-12-03 |
Family
ID=68663942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910770631.4A Pending CN110530829A (zh) | 2019-08-20 | 2019-08-20 | 一种基于荧光的早期药物筛选方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110530829A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113607707A (zh) * | 2021-08-05 | 2021-11-05 | 国家食品安全风险评估中心 | 一种基于钠离子通道Nav1.1的海洋神经毒素荧光快速筛查方法 |
CN114774512A (zh) * | 2022-04-15 | 2022-07-22 | 杭州圣域生物医药科技有限公司 | 一种地高辛标记以DNA聚合酶θ为靶点的早期药物筛选方法 |
CN115786339A (zh) * | 2022-10-24 | 2023-03-14 | 北京爱思益普生物科技股份有限公司 | 一种tmej检测底物、其制备方法及应用 |
CN115927526A (zh) * | 2023-01-05 | 2023-04-07 | 北京爱思益普生物科技股份有限公司 | 一种hERG通道的高通量检测方法及其应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1842709A (zh) * | 2003-07-10 | 2006-10-04 | 塞诺米克斯公司 | 使用表达人的ENaC的卵母细胞的改进的电生理测定法和用于在使用膜电位报告染料的测定中提高ENaC增强子功效的PHENAMIL的用途 |
CN101300489A (zh) * | 2005-11-03 | 2008-11-05 | 红点生物公司 | Trpm5离子通道的高通量筛选实验 |
CN101848717A (zh) * | 2007-10-26 | 2010-09-29 | 塞诺菲-安万特股份有限公司 | 诺孕酯作为trpc3、trpc6和trpc7离子通道选择性抑制剂的用途 |
CN101868539A (zh) * | 2007-10-18 | 2010-10-20 | Seoul大学校产学协力团 | 鉴定调变钙活化型氯通道活性的药剂的方法 |
CN104449670A (zh) * | 2014-11-11 | 2015-03-25 | 山东大学 | 一种苯基呋喃类hERG钾离子通道的小分子荧光探针及其应用 |
-
2019
- 2019-08-20 CN CN201910770631.4A patent/CN110530829A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1842709A (zh) * | 2003-07-10 | 2006-10-04 | 塞诺米克斯公司 | 使用表达人的ENaC的卵母细胞的改进的电生理测定法和用于在使用膜电位报告染料的测定中提高ENaC增强子功效的PHENAMIL的用途 |
CN101300489A (zh) * | 2005-11-03 | 2008-11-05 | 红点生物公司 | Trpm5离子通道的高通量筛选实验 |
CN101868539A (zh) * | 2007-10-18 | 2010-10-20 | Seoul大学校产学协力团 | 鉴定调变钙活化型氯通道活性的药剂的方法 |
CN101848717A (zh) * | 2007-10-26 | 2010-09-29 | 塞诺菲-安万特股份有限公司 | 诺孕酯作为trpc3、trpc6和trpc7离子通道选择性抑制剂的用途 |
CN104449670A (zh) * | 2014-11-11 | 2015-03-25 | 山东大学 | 一种苯基呋喃类hERG钾离子通道的小分子荧光探针及其应用 |
Non-Patent Citations (1)
Title |
---|
余蓉: "《生物化学》", 31 July 2015 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113607707A (zh) * | 2021-08-05 | 2021-11-05 | 国家食品安全风险评估中心 | 一种基于钠离子通道Nav1.1的海洋神经毒素荧光快速筛查方法 |
CN113607707B (zh) * | 2021-08-05 | 2024-03-12 | 国家食品安全风险评估中心 | 一种基于钠离子通道Nav1.1的海洋神经毒素荧光快速筛查方法 |
CN114774512A (zh) * | 2022-04-15 | 2022-07-22 | 杭州圣域生物医药科技有限公司 | 一种地高辛标记以DNA聚合酶θ为靶点的早期药物筛选方法 |
CN114774512B (zh) * | 2022-04-15 | 2023-02-03 | 杭州圣域生物医药科技有限公司 | 一种地高辛标记以DNA聚合酶θ为靶点的早期药物筛选方法 |
CN115786339A (zh) * | 2022-10-24 | 2023-03-14 | 北京爱思益普生物科技股份有限公司 | 一种tmej检测底物、其制备方法及应用 |
CN115927526A (zh) * | 2023-01-05 | 2023-04-07 | 北京爱思益普生物科技股份有限公司 | 一种hERG通道的高通量检测方法及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110530829A (zh) | 一种基于荧光的早期药物筛选方法 | |
Zheng et al. | High throughput assay technologies for ion channel drug discovery | |
Fang et al. | Interleukin-17 alteration in first-episode psychosis: a meta-analysis | |
CN109142710B (zh) | 一种快速灵敏检测河豚毒素ttx的方法 | |
Watson et al. | Extraction, identification, and functional characterization of a bioactive substance from automated compound-handling plastic tips | |
US20140199704A1 (en) | Multiplex cell signalling assays | |
Kufareva et al. | A novel approach to quantify G-protein-coupled receptor dimerization equilibrium using bioluminescence resonance energy transfer | |
Giudice et al. | Optimization and standardization of fluorescent cell barcoding for multiplexed flow cytometric phenotyping | |
Yeyeodu et al. | A rapid, inexpensive high throughput screen method for neurite outgrowth | |
CN110006866B (zh) | 一种阿片类活性物质的通用检测方法及其检测试剂盒 | |
CN108387743B (zh) | 一种检测缺陷型精神分裂症外周血蛋白标志物的液相芯片及其检测方法 | |
US20060008849A1 (en) | Methods for measuring chloride channel conductivity | |
CN107121553A (zh) | 一种气‑液界面暴露系统联合高内涵技术定量检测1,3‑丁二烯致细胞dna损伤的方法 | |
L Chang et al. | Quantification of intracellular proteins and monitoring therapy using flow cytometry | |
US20140335545A1 (en) | Method for detecting compound-binding protein | |
EP1778860B1 (en) | Methods for determining the potency, specificity, and toxicity of hematopoietic prostaglandin d2 synthase | |
CN108801996A (zh) | 一种检测外周血神经元中磷酸化α突触核蛋白阳性细胞占比的方法 | |
Proudfoot et al. | Glossary of terms used in biomolecular screening (IUPAC Recommendations 2011) | |
Manandhar et al. | Evaluating opioid-mediated adenylyl cyclase inhibition in live cells using a BRET-based assay | |
CN107064086A (zh) | 一种基于高内涵技术定量分析苯并[a]芘致细胞DNA损伤的方法 | |
KR20080004994A (ko) | 형광 이미징법을 이용한 5-ht6 수용체 리간드 고효율검색법 | |
Chen et al. | Application of large-scale transient transfection to cell-based functional assays for ion channels and GPCRs | |
Perez de Arce et al. | Co-culture Synaptogenic Assay: A New Look at Fluorescence Reporters and Technological Devices | |
Fang | Cellular assays | |
CN112280741A (zh) | FRT细胞株在制备筛选Piezo1调节剂的制剂或试剂盒中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240319 Address after: Room 101, 1st Floor, Building 16, No. 18 Science and Technology Innovation 13th Street, Daxing District, Beijing, 100176 Applicant after: ICE BIOSCIENCE Inc. Country or region after: Zhong Guo Address before: Building 4, 3rd Floor, No. 35 Jinghai Third Road, Beijing Economic and Technological Development Zone, Daxing District, Beijing, 100176 Applicant before: ICE BIOSCIENCE Inc. Country or region before: Zhong Guo Applicant before: Xuzhou aisiyipu Biotechnology Co.,Ltd. |
|
TA01 | Transfer of patent application right |